SLC5A2 and diabetic kidney disease: The primary nephroprotective mechanisms of empagliflozin, which include reducing intraglomerular pressure, improving sodium excretion, and decreasing renal inflammation, indicate that SGLT2 inhibitors should be favored in cases of diabetic kidney disease.